FDA Rejects ITM’s Radiopharmaceutical ITM-11 Over Manufacturing and Third-Party Facility Deficiencies
On August 7, 2026, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding ITM Isotope Technologies Munich SE’s (ITM) New Drug Application (NDA) for 177Lu-edotreotide (ITM-11), an investigational targeted radiotherapeutic for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The decision was a major surprise for the radiopharmaceutical sector, as ITM-11 was highly anticipated as a key competitor to Novartis’s blockbuster Lutathera.
Crucially, the FDA did not raise any concerns regarding the clinical or nonclinical efficacy and safety data of ITM-11, leaving the pivotal Phase 3 COMPETE trial package fully intact. Instead, the rejection was entirely driven by Chemistry, Manufacturing, and Controls (CMC) issues and third-party commercial facility inspection findings. ITM has expressed confidence in the therapeutic potential of ITM-11 and stated its intention to address the regulatory feedback and resubmit the NDA.
Key Details and Impact
- No Clinical Deficiencies: The FDA did not request any additional clinical or nonclinical trials, confirming that the clinical package is robust. The pivotal Phase 3 COMPETE trial (NCT03049189) previously met its primary endpoint, showing statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to everolimus.
- Manufacturing Bottlenecks: The rejection highlights the ongoing operational and supply chain complexities inherent in the radiopharmaceutical space. Producing and distributing therapeutic radioisotopes requires highly specialized, sterile, third-party commercial facilities operating under tight time constraints due to radioactive decay.
- Competitive Landscape: The delay leaves Novartis's Lutathera without a direct competitor in the GEP-NET market for the immediate future, though ITM-11 is also being evaluated in the COMPOSE Phase 3 study for well-differentiated, aggressive Grade 2 or Grade 3 somatostatin receptor-positive GEP-NETs.
Verbatim Quotes
From the official ITM Press Release:
"The CRL stated that the FDA is unable to approve the NDA in its present form and cited CMC- and third-party commercial facility-related items that must be addressed before the application can be approved. The FDA did not identify any concerns regarding the clinical or nonclinical data package or safety profile of ITM-11." — ITM Press Release
From Dr. Andrew Cavey, CEO of ITM:
"Our confidence in ITM-11’s therapeutic potential has not wavered, and we are committed to working closely with the FDA and our partners to address the items outlined in the CRL. Our pivotal COMPETE trial data package stands, and our goal remains unchanged as we work toward bringing ITM-11 to patients living with advanced GEP-NETs." — ITM Press Release